Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320102 | 0.86 | PDK4 (0.53) | PDK4ELANECNR1HTR6KDM1A | |
| SCHEMBL3436177 | 0.85 | PDK4 (0.52) | PDK4CNR1HTR6JAK1EED | |
| SCHEMBL5106249 | 0.84 | CNR1 (0.55) | PDK4CNR1HTR6JAK1GRM1 | |
| SCHEMBL1763322 | 0.83 | ELANE (0.54) | PDK4ELANECNR1HTR6KDM1A | |
| SCHEMBL2357533 | 0.83 | NAMPT (0.57) | PDK4ELANEHTR6KDM1AGRM1 | |
| SCHEMBL17672676 | 0.83 | ALK (0.42) | ELANEJAK1NAMPTALKBTK | |
| SCHEMBL17393489 | 0.82 | PDK4 (0.53) | PDK4ELANECNR1HTR6JAK1 | |
| SCHEMBL4881377 | 0.81 | SLC6A4 (0.63) | PDK4ELANECNR1HTR6JAK1 | |
| SCHEMBL23538852 | 0.81 | PDK4 (0.52) | PDK4ELANECNR1HTR6JAK1 | |
| SCHEMBL29744727 | 0.81 | PDK4 (0.52) | PDK4ELANECNR1HTR6JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016055947-A1 | ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016046782-A1 | IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-03-31 | — | — | WO | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PDK4 1001/4885ELANE 2732/4885CNR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.